This is a randomized, controlled, single-centre phase II superiority trial to determine the
efficacy of 12 weeks of celecoxib (50 mg or 100 mg orally twice daily, dosed based on weight)
compared to placebo as an adjunct to treatment-as-usual in children and youth with
moderate-to-severe obsessive-compulsive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
University of British Columbia
Collaborators:
BC Children's Hospital Research Institute International Obsessive-Compulsive Disorder Foundation Obsessive Compulsive Foundation